RISK

Trading carries substantial risk of loss. Prop evaluation fees are typically non-refundable and the majority of traders do not pass first attempts. This comparison is for informational purposes only and does not constitute financial advice. Read full risk warning

HEAD-TO-HEAD COMPARISON · 2026

Monevis Funding vs MiFunder

Side-by-side comparison of trust scores, profit splits, payout speed, and real trader reviews. Independent data — no sponsored rankings.

MNVF

Monevis Funding

EST. 2024

MIFD

MiFunder

MONEVIS FUNDING

METRIC

MIFUNDER

0/100TIE

TRUST SCORE

TIE0/100

0/5TIE

RATING

TIE0/5

—

PROFIT SPLIT

—

MAX FUNDING

—

MIN COST

—

PAYOUT DAYS

—

PASS RATE

—

0TIE

REVIEW COUNT

TIE0

MONEVIS FUNDING DETAILS

STEPS: -phase
DRAWDOWN: Static

MIFUNDER DETAILS

STEPS: -phase

Monevis Funding PROS

+Static drawdown type provides a fixed, predictable risk boundary, which some traders prefer for planning.
+Czech Republic is an EU-member jurisdiction, which may offer relevant regulatory context.
+No platform or market data is available to assess further strengths.
+No funding or cost data is provided to compare against industry benchmarks.

Monevis Funding CONS

−Founded in 2024, making Monevis Funding a very new firm with limited operational track record.
−No profit split, max funding, or challenge cost data is available for comparison against industry averages.
−Lack of transparency around key metrics is a concern for traders making informed decisions.

MiFunder PROS

+No data is available to identify any pros for MiFunder at this time.
+No platform or market information is provided to assess trading conditions.
+No funding or cost data is available to compare against industry benchmarks.
+No profit split or payout data exists to evaluate trader compensation.

MiFunder CONS

−No data whatsoever is available for MiFunder, making any evaluation impossible.
−Complete absence of key metrics such as drawdown, profit split, and funding is a significant transparency concern.
−Traders have no basis for comparison against industry averages with zero data disclosed.

PROPDNA VERDICT